Evidence map›Paper›PMID 39659606›Full record

ArticleRSC advances2024

Molecular dynamics study on the effect of the N1 neuraminidase double mutant G147R/H274Y on oseltamivir sensitivity.

Ardiana Ilham Nurrohman, Hery Suwito, Ni Nyoman Tri Puspaningsih, Kautsar Ul Haq

Abstract read
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ardiana Ilham NurrohmanBioinformatics Research Group, University-CoE-Research Center for Bio-Molecule Engineering (BIOME), Universitas Airlangga Surabaya 60115 Indonesia.
Hery SuwitoDepartment of Chemistry, Faculty of Science and Technology, Universitas Airlangga Surabaya 60115 Indonesia kautsar.ul.haq@fst.unair.ac.id.
Ni Nyoman Tri PuspaningsihProteomic Laboratory, University-CoE-Research Center for Bio-Molecule Engineering (BIOME), Universitas Airlangga Surabaya 60115 Indonesia.
Kautsar Ul HaqBioinformatics Research Group, University-CoE-Research Center for Bio-Molecule Engineering (BIOME), Universitas Airlangga Surabaya 60115 Indonesia.ORCID https://orcid.org/0000-0002-0584-5040

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibition of neuraminidase is the most prominent target in influenza medication using oseltamivir as an inhibitor. However, the emerging resistance of neuraminidase toward oseltamivir due to mutation reduces the efficacy of oseltamivir. The generally reported mutation is a single mutation at H274Y, which declines the sensitivity of oseltamivir by almost 900 folds compared to the wild-type variant. Moreover, an additional mutation at G147R increases the resistance by more than 2000 folds. However, sufficient studies on the resistance mechanism of this variant have not yet been reported. Therefore, we simulated four neuraminidase proteins comprising wild-type (WT), G147R, H274Y, and G147R/H274Y using molecular dynamics simulation to disclose the binding mechanism of oseltamivir. Trajectory analysis was conducted to reveal structural stability and flexibility. Furthermore, end-point free binding energy calculations were conducted. The energy decomposition of each residue was also calculated. The end-point energy calculation showed a similar result to that of experimental data. The energy decomposition analysis revealed that G147R/H274Y showed significant reduction in oseltamivir (OST) interaction with R118. Salt-bridge disruption caused by R224-E276 was also observed. Modification to enhance the polarity of the inhibitor might be useful in overcoming these changes. However, it should be noted that such changes could worsen the pharmacokinetic property of the inhibitor. It is hoped that these findings will provide useful insights for the development of an anti-influenza drug that can withstand the mutant variant.

Identifiers

PMID39659606
PMCPMC11629752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.